Skip to main content

Advertisement

SpringerLink
Log in

Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Five patients at risk for primary central nervous system lymphoma (PCNSL) recurrence were treated with high-dose methylprednisolone, (HDMP) to prevent ‘trafficking’ of malignant lymphocytes into the central nervous system (CNS). HDMP was chosen because of its ability to stabilize the ‘blood brain barrier (BBB)’. Three men with newly diagnosed PCNSL, ages 62, 76 and 78 y, whose survival was projected to be 6.6 months, began treatment after achieving complete response (CR) to initial radiation therapy alone and survived 27, 37 and 59 months after treatment. In none was death from recurrent disease in CNS but one patient did die of systemic non-Hodgkin’s lymphoma (NHL) five years after PCNSL diagnosis. A 20 y old man was treated with HDMP after successful combined modality therapy and is alive 75+months after initial diagnosis without evidence of disease recurrence. A 34 y old man relapsed after combined modality initial treatment and failed to respond to HDMP when treatment was begun after unsuccessful salvage therapy; he died of disease 12 months after initial diagnosis. There were no treatment complications. The promising results in this pilot study from the basis for a North Central Cancer Treatment Group (NCCTG) 96-73-51, a Phase 2 clinical trial of brain radiotherapy and HDMP for PCNSL patients 70 y of age and older, a group of patients at high risk for toxicity from intensive combined modality therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hochberg FH, Miller DC. Primary central nervous system lymphoma.J Neurosurg 1988;68: 835–853.

    Article  CAS  PubMed  Google Scholar 

  2. O’Neill BP, Illig J. Primary central nervous system lymphoma.Mayo Clinic Proc 1989;64: 1005–1020.

    Article  Google Scholar 

  3. O’Neill BP, Dinapoli RP, Kurtin PJ, Habermann TM. Occult systemic non-Hodgkin’s lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?J Neuro-oncology 1995;25: 67–71.

    Article  Google Scholar 

  4. Jack CR, Jr, O’Neill BP, Banks PM, Reese DF. Primary central nervous system lymphoma: histologic subtypes and CT appearance.Radiology 1988;167: 211–215.

    Article  PubMed  Google Scholar 

  5. O’Neill BP, Wang C-H, O’Fallon JR. Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52.Int J Radiat Oncol Biol Phys 1999;43: 559–563.

    Article  PubMed  Google Scholar 

  6. Nelson DFet al. Non-Hodgkin’s lymphoma of brain. Can high dose, large volume radiation therapy improve survival? report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.Int J Radiat Oncol Biol Phys 1992;23: 9–17.

    Article  CAS  PubMed  Google Scholar 

  7. Bessell EMet al. Primary non-Hodgkin’s lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.J Clin Oncol 1996;14: 945–954.

    Article  CAS  PubMed  Google Scholar 

  8. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma.J Clin Oncol 1998;16: 859–863.

    Article  CAS  PubMed  Google Scholar 

  9. Vaquero J, Martinez R, Rossi R, Lopez R. Primary cerebral lymphoma: the ‘ghost tumor’.J Neurosurg 1984;60: 174–176.

    Article  CAS  PubMed  Google Scholar 

  10. Ott RJet al. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma.Eur J Cancer 1991;27: 1356–1361.

    Article  CAS  PubMed  Google Scholar 

  11. Ueda FTet al. MR imaging of primary intracranial malignant lymphoma.Radiation Medicine 1995;13: 51–57.

    CAS  PubMed  Google Scholar 

  12. Molnar PP, O’Neill BP, Scheithauer BW, Groothuis DR. Endothelial cell death affects the blood-tumor barrier in primary CNS lymphoma. Ultrastructural observations and review of the literature.Neuro-Oncology (in press).

  13. Hirano A, Ghatak NR, Becker NH, Zimmerman HM. A comparison of the fine structure of small blood vessels in intracranial and retroperitoneal malignant lymphomas.Acta Neuropathol 1974;27: 93–104.

    Article  CAS  PubMed  Google Scholar 

  14. DeAngelis LM. Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan.Ann Neurol 1993;33: 308–311.

    Article  CAS  PubMed  Google Scholar 

  15. Allegranza A, Mariani C, Giardini R, Brambilla MC, Boeri R. Primary malignant lymphomas of the central nervous system: a histological and immunohistological study of 12 cases.Histopathology 1984;8: 781–791.

    Article  CAS  PubMed  Google Scholar 

  16. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma.J Neurosurg 1989;70: 190–194.

    Article  CAS  PubMed  Google Scholar 

  17. Shibamoto Yet al. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine, doxorubicin, cyclophosphamide, prednisolone chemotherapy.Cancer 1990;65: 1907–1912.

    Article  CAS  PubMed  Google Scholar 

  18. Amadori Set al. Sequential combination of systemic high-dose, ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma.J Clin Oncol 1984;2: 98–101.

    Article  CAS  PubMed  Google Scholar 

  19. Loeffler JSet al. Primary lymphomas of the CNS: patterns of failure and factors that influence survival.J Clin Oncol 1985;3: 490–494.

    Article  CAS  PubMed  Google Scholar 

  20. Posner JR. Intracranial metastases.Neurologic Complications of Cancer. FA Davis: Philadelphia, 1995, p 109.

    Google Scholar 

  21. Azzarelli B, Easterling K, Norton JA. Leukemic cell-endothelial cell interaction in leukemic cell dissemination.Lab Invest 1989;60: 45–64.

    CAS  PubMed  Google Scholar 

  22. Dunne JW, Harper CG, Pamphlett R. Intramedullary spinal cord metastases: A clinical and pathological study of nine cases.Quart J Med 1986;61: 1003–1020.

    CAS  PubMed  Google Scholar 

  23. Bashir R, Coakham H, Hochberg F. Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanisms for lymphoma homing to the brain.J Neuro-oncol 1992;12: 103–110.

    Article  CAS  Google Scholar 

  24. Wilcox CEet al. Endothelial cell expression of the intracellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental encephalomyelitis.J Neuroimmunol 1990;30: 43–51.

    Article  CAS  PubMed  Google Scholar 

  25. Washington Ret al. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis.Ann Neurol 1994;35: 89–87.

    Article  CAS  PubMed  Google Scholar 

  26. Frenette PS, Wagner DD. Adhesion molecules—Part I: cell adhesion molecules.N Engl J Med 1996;334: 1526–1529.

    Article  CAS  PubMed  Google Scholar 

  27. Frenette PS, Wagner DD. Adhesion molecules—Part II: blood vessels and blood cells.N Engl J Med 1996;335: 43–45.

    Article  CAS  PubMed  Google Scholar 

  28. Canella B, Cross AH, Raine CS. Adhesion-related molecules in the central nervous system: upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis.Lab Invest 1991;1: 23–31.

    Google Scholar 

  29. Oliveri RLet al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study.Neurology 1998;50: 1833–1836.

    Article  CAS  PubMed  Google Scholar 

  30. Durelli Let al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.Neurology 1986;36: 238–243.

    Article  CAS  PubMed  Google Scholar 

  31. Trojano Met al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DPTA magnetic resonance imaging enhancement and cerebrospinal fluid findings.Neurology 1996;46: 1535–1541.

    Article  Google Scholar 

  32. Steffen BJ, Butcher EC, Engelhardt B. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse.Am J Pathol 1994;145: 189–201.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Gametchu B. Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis.Science 1987;236: 456–461.

    Article  CAS  PubMed  Google Scholar 

  34. Ferreri AJM, Reni M, Villa E. Primary central nervous system lymphoma in immunocompetent patients.Cancer Treat Rev 1995;21: 415–446.

    Article  CAS  PubMed  Google Scholar 

  35. Blay J-Yet al. Late neurological toxicity after the treatment of primary central nervous system lymphoma; multivariate analysis of 208 patients.J Clin Oncol 1998;16: 864–871.

    Article  CAS  PubMed  Google Scholar 

  36. Schaller C, Kelly PJ. Primary central nervous system lymphoma (PCNSL): does age and histology at presentation affect outcome?.Zent Neurochiurg 1996;57: 56–62.

    Google Scholar 

  37. Miller DCet al. Pathology with clinical correlation of primary central nervous system non-Hodgkin’s lymphoma.Cancer 1994;74: 1383–1397.

    Article  CAS  PubMed  Google Scholar 

  38. Gill PSet al. Primary central nervous system lymphoma in homosexual men: clinical, immunologic and pathologic features.Am J Med 1985;78: 742–748.

    Article  CAS  PubMed  Google Scholar 

  39. Corn BW, Marcus SM, Topham A, Hauck W, Curran WJ Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?Cancer 1997;79: 2409–2413.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    TM Habermann & TE Witzig

  2. Mayo Clinic Cancer Center, Rochester, MN, USA

    TM Habermann & TE Witzig

  3. Department of Neurology, Mayo Clinic, Mayo Clinic Cancer Center, 200 First Street SW, 55905, Rochester, MN, USA

    BP O’Neill & M Rodriguez

Authors
  1. BP O’Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. TM Habermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. TE Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to BP O’Neill.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Neill, B., Habermann, T., Witzig, T. et al. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med Oncol 16, 211–215 (1999). https://doi.org/10.1007/BF02906134

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02906134

Keywords

Search

Navigation